Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • Angiotensin (1-7) Mechanisms, Clinical Applications, and Res

    2025-07-30

    Angiotensin (1-7): Mechanisms, Clinical Applications, and Research Perspectives in Cardiovascular and Renal Therapeutics

    Introduction
    Angiotensin (1-7) [Ang-(1-7)] is a biologically active heptapeptide of the renin-angiotensin system (RAS), recognized for its counter-regulatory effects against the classical angiotensin II (Ang II) axis. Unlike Ang II, which promotes vasoconstriction, inflammation, fibrosis, and proliferation, Ang-(1-7) exerts vasodilatory, anti-inflammatory, anti-fibrotic, and anti-proliferative actions primarily via the Mas receptor (Santos et al., 2003, Circulation Research). The peptide is generated from Ang I or Ang II through the enzymatic activity of angiotensin-converting enzyme 2 (ACE2), neprilysin, or prolyl endopeptidase. Its unique mechanism of action positions Ang-(1-7) as a promising therapeutic agent in cardiovascular, renal, and metabolic diseases, offering a novel approach to modulating RAS beyond traditional ACE inhibitors or angiotensin receptor blockers (ARBs).

    Clinical Value and Applications
    The clinical value of Ang-(1-7) lies in its ability to counterbalance the deleterious effects of Ang II, providing therapeutic benefits in several disease states:

    [Related: erastin structure] 1. **Cardiovascular Diseases**: Ang-(1-7) has demonstrated efficacy in reducing blood pressure, improving endothelial function, and attenuating cardiac remodeling in preclinical and early clinical studies (Santos et al., 2018, Hypertension). Its vasodilatory and anti-fibrotic properties are particularly valuable in the management of hypertension, heart failure, and myocardial infarction.

    2. **Renal Disorders**: In models of chronic kidney disease (CKD) and diabetic nephropathy, Ang-(1-7) mitigates glomerular injury, reduces proteinuria, and preserves renal function by inhibiting inflammation and fibrosis (Pinheiro et al., 2012, Kidney International).

    [Related: CYC202] 3. **Metabolic Syndrome and Diabetes**: Ang-(1-7) improves insulin sensitivity, glucose uptake, and lipid metabolism, suggesting potential utility in metabolic syndrome and type 2 diabetes management (Santos et al., 2018, Hypertension).

    4. **Pulmonary Hypertension and Fibrosis**: The peptide has shown promise in experimental models of pulmonary arterial hypertension and lung fibrosis, attributed to its anti-proliferative and anti-inflammatory effects (Shenoy et al., 2010, American Journal of Respiratory and Critical Care Medicine).

    [Related: LDP-341] 5. **Neurological Disorders**: Emerging evidence suggests neuroprotective roles for Ang-(1-7), including attenuation of neuroinflammation and oxidative stress in models of stroke and neurodegeneration (Mecca et al., 2011, Experimental Neurology).

    Key Challenges and Pain Points Addressed
    Current RAS-targeted therapies, such as ACE inhibitors and ARBs, primarily inhibit the actions of Ang II but do not enhance the protective arm of the RAS mediated by Ang-(1-7). This limitation may result in incomplete suppression of pathological processes, particularly in patients with advanced cardiovascular or renal disease. Key challenges addressed by Ang-(1-7) include:

    - **Incomplete RAS Modulation**: Traditional therapies block Ang II but do not restore or augment Ang-(1-7) levels, potentially limiting therapeutic efficacy (Santos et al., 2018, Hypertension).

    - **Adverse Effects of Current Therapies**: ACE inhibitors and ARBs are associated with adverse events such as cough, angioedema, and hyperkalemia, which may limit their use in certain populations.

    - **Organ Protection Beyond Blood Pressure Control**: Ang-(1-7) offers direct anti-fibrotic, anti-inflammatory, and anti-proliferative effects, which are not fully achieved by conventional RAS blockade.

    - **Therapeutic Gaps in Metabolic and Pulmonary Diseases**: There is a lack of effective RAS-targeted therapies for metabolic syndrome, diabetes, and pulmonary hypertension, areas where Ang-(1-7) shows promise.

    Literature Review
    A growing body of preclinical and clinical research supports the therapeutic potential of Ang-(1-7):

    1. **Santos et al. (2003, Circulation Research)**: This seminal study demonstrated that Ang-(1-7) acts as an endogenous ligand for the Mas receptor, mediating vasodilatory and anti-proliferative effects. The authors established the foundation for understanding Ang-(1-7) as a counter-regulatory peptide within the RAS.

    2. **Shenoy et al. (2010, American Journal of Respiratory and Critical Care Medicine)**: In a rat model of pulmonary hypertension, Ang-(1-7) administration attenuated right ventricular hypertrophy, reduced pulmonary vascular resistance, and decreased inflammatory cytokine expression, highlighting its potential in pulmonary vascular diseases.

    3. **Pinheiro et al. (2012, Kidney International)**: This study reported that Ang-(1-7) treatment in diabetic rats reduced proteinuria, glomerulosclerosis, and renal inflammation, supporting its renoprotective effects in diabetic nephropathy.

    4. **Mecca et al. (2011, Experimental Neurology)**: The authors found that intracerebroventricular administration of Ang-(1-7) reduced infarct size and improved neurological outcomes in a mouse model of ischemic stroke, suggesting neuroprotective properties.

    5. **Santos et al. (2018, Hypertension)**: This comprehensive review summarized clinical and experimental evidence for Ang-(1-7) in cardiovascular and metabolic diseases, emphasizing its potential as a therapeutic agent and the need for further clinical trials.

    6. **Ishiyama et al. (2004, Hypertension)**: The study demonstrated that Ang-(1-7) infusion in hypertensive rats led to significant reductions in blood pressure and cardiac fibrosis, mediated through the Mas receptor.

    7. **Ferreira et al. (2012, Clinical Science)**: This review highlighted the anti-inflammatory and anti-fibrotic actions of Ang-(1-7) in various organ systems, reinforcing its broad therapeutic potential.

    Experimental Data and Results
    Experimental studies have consistently demonstrated the beneficial effects of Ang-(1-7) in various disease models:

    - **Cardiovascular Effects**: In hypertensive animal models, chronic administration of Ang-(1-7) resulted in significant reductions in systolic blood pressure, improved endothelial-dependent vasodilation, and decreased cardiac hypertrophy and fibrosis (Ishiyama et al., 2004, Hypertension). These effects were abolished by Mas receptor antagonists, confirming receptor specificity.

    - **Renal Protection**: In diabetic nephropathy models, Ang-(1-7) reduced albuminuria, glomerulosclerosis, and renal inflammation, with associated decreases in pro-inflammatory cytokines and fibrotic markers (Pinheiro et al., 2012, Kidney International).

    - **Metabolic Benefits**: Ang-(1-7) improved glucose tolerance and insulin sensitivity in rodent models of metabolic syndrome, with reductions in adipose tissue inflammation and improved lipid profiles (Santos et al., 2018, Hypertension).

    - **Pulmonary and Neurological Outcomes**: In models of pulmonary hypertension, Ang-(1-7) reduced right ventricular pressure and vascular remodeling (Shenoy et al., 2010, AJRCCM). In stroke models, it decreased infarct size and improved neurological recovery (Mecca et al., 2011, Experimental Neurology).

    - **Safety and Tolerability**: Preclinical studies indicate that Ang-(1-7) is well-tolerated, with minimal adverse effects at therapeutic doses. However, clinical safety data remain limited and warrant further investigation.

    Usage Guidelines and Best Practices
    The optimal use of Ang-(1-7) in research and potential clinical settings requires careful consideration of dosing, administration route, and monitoring:

    - **Formulation and Administration**: Ang-(1-7) is available as a synthetic peptide for research use, typically administered via intravenous, subcutaneous, or intraperitoneal routes in animal studies. For translational research, development of stable oral or inhaled formulations is ongoing (Santos et al., 2018, Hypertension).

    - **Dosage**: Effective doses in animal studies range from 24 to 576 μg/kg/day, depending on the disease model and route of administration (Ishiyama et al., 2004, Hypertension). Dose-response studies are recommended to determine optimal therapeutic windows.

    - **Monitoring**: Assessment of blood pressure, renal function, cardiac structure, and inflammatory markers is essential to evaluate efficacy and safety. Use of Mas receptor antagonists (e.g., A-779) can confirm specificity of observed effects.

    - **Combination Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 60 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11472331